Zeng et al. [33] recently reported that patients with dMMR tumors accounted for 11.8% of the CRC population, while those with PMS2 deletion accounted for 8.3% of the total CRC population, meaning that 70.3% of the dMMR tumor patients in their cohort had PMS2 protein deletion, which is consistent with the presence of PMS2 deletion in 61.3% of dMMR rectal cancer patients in our cohort. This evidence concerns the gene PMS2 and colorectal carcinoma.